Faster access to new drugs doesn’t always mean better treatment

US President Donald Trump recently chose an adviser to a large pharmaceutical company to lead the country’s drug regulation agency. Scott Gottlieb – who reportedly sits on the boards of several small drug companies and is an adviser to GlaxoSmithKline – is expected to introduce greater flexibility to the evidence standards used by the Food ...

Already a member?

Login to keep reading.

© 2021 the limbic